Short-term effectiveness of bupropion for assisting smoking cessation in general practice

Nicholas A. Zwar*, Alia Nasser, Elizabeth Comino, Robyn L. Richmond

*Corresponding author for this work

Research output: Contribution to journalLetterResearch

7 Citations (Scopus)

Abstract

To the Editor: As noted in the letter by Chapman and Jamrozik,1 there was substantial prescribing of bupropion sustained release (Zyban SR; GlaxoSmithKline) following its Pharmaceutical Benefits Scheme (PBS) listing from 1 February 2001. The drug has been the subject of extensive publicity following reports of adverse drug reactions and deaths of patients while taking bupropion. Although bupropion has been shown to be effective in two key clinical trials,2,3 there are no studies of effectiveness when prescribed in the context of Australian general practice.
Original languageEnglish
Pages (from-to)277-278
Number of pages2
JournalMedical Journal of Australia
Volume177
Issue number5
Publication statusPublished - 2 Sep 2002
Externally publishedYes

Fingerprint Dive into the research topics of 'Short-term effectiveness of bupropion for assisting smoking cessation in general practice'. Together they form a unique fingerprint.

  • Cite this